Safely targeting autoimmunity in type 1 diabetes: The MonoPepT1De trial

Yuk Fun Liu; Mark Peakman; Colin M. Dayan

doi:10.1002/pdi.1764

Safely targeting autoimmunity in type 1 diabetes: The MonoPepT1De trial

Yuk Fun Liu
, Mark Peakman
, Colin M. Dayan

Immunology and Immunotherapy

Research output: Contribution to journal › Review article › peer-review

Abstract

PIT is a safe approach to immunoregulation in T1D with PI C19-A3 having unique properties which may be the key to switching immune attack to tolerance. In HLA DR4 positive individuals, PI C19-A3 PIT may form part of the strategy to enhance regulatory mechanisms, although full arrest of the autoimmune attack in T1D may hinge upon optimizing timing, dosing and potentially amplifying response with additional peptides. The MonoPepT1De trial aims to further establish the safety profile of this treatment and elucidate on some of these issues. COPYRIGHT

Original language	English
Pages (from-to)	148-150a
Journal	Practical Diabetes
Volume	30
Issue number	4
DOIs	https://doi.org/10.1002/pdi.1764
Publication status	Published - May 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

ASJC Scopus subject areas

Internal Medicine
Endocrinology, Diabetes and Metabolism

Access to Document

10.1002/pdi.1764

Cite this

@article{9f8aac2221784abc937787f89606931d,

title = "Safely targeting autoimmunity in type 1 diabetes: The MonoPepT1De trial",

abstract = "PIT is a safe approach to immunoregulation in T1D with PI C19-A3 having unique properties which may be the key to switching immune attack to tolerance. In HLA DR4 positive individuals, PI C19-A3 PIT may form part of the strategy to enhance regulatory mechanisms, although full arrest of the autoimmune attack in T1D may hinge upon optimizing timing, dosing and potentially amplifying response with additional peptides. The MonoPepT1De trial aims to further establish the safety profile of this treatment and elucidate on some of these issues. COPYRIGHT",

author = "Liu, \{Yuk Fun\} and Mark Peakman and Dayan, \{Colin M.\}",

year = "2013",

month = may,

doi = "10.1002/pdi.1764",

language = "English",

volume = "30",

pages = "148--150a",

journal = "Practical Diabetes",

issn = "2047-2897",

publisher = "John Wiley \& Sons",

number = "4",

}

TY - JOUR

T1 - Safely targeting autoimmunity in type 1 diabetes

T2 - The MonoPepT1De trial

AU - Liu, Yuk Fun

AU - Peakman, Mark

AU - Dayan, Colin M.

PY - 2013/5

Y1 - 2013/5

N2 - PIT is a safe approach to immunoregulation in T1D with PI C19-A3 having unique properties which may be the key to switching immune attack to tolerance. In HLA DR4 positive individuals, PI C19-A3 PIT may form part of the strategy to enhance regulatory mechanisms, although full arrest of the autoimmune attack in T1D may hinge upon optimizing timing, dosing and potentially amplifying response with additional peptides. The MonoPepT1De trial aims to further establish the safety profile of this treatment and elucidate on some of these issues. COPYRIGHT

AB - PIT is a safe approach to immunoregulation in T1D with PI C19-A3 having unique properties which may be the key to switching immune attack to tolerance. In HLA DR4 positive individuals, PI C19-A3 PIT may form part of the strategy to enhance regulatory mechanisms, although full arrest of the autoimmune attack in T1D may hinge upon optimizing timing, dosing and potentially amplifying response with additional peptides. The MonoPepT1De trial aims to further establish the safety profile of this treatment and elucidate on some of these issues. COPYRIGHT

UR - https://www.scopus.com/pages/publications/84881335428

U2 - 10.1002/pdi.1764

DO - 10.1002/pdi.1764

M3 - Review article

AN - SCOPUS:84881335428

SN - 2047-2897

VL - 30

SP - 148-150a

JO - Practical Diabetes

JF - Practical Diabetes

IS - 4

ER -

Safely targeting autoimmunity in type 1 diabetes: The MonoPepT1De trial

Abstract

UN SDGs

ASJC Scopus subject areas

Access to Document

Fingerprint

Cite this